Investigational Drug Details
| Drug ID: | D293 |
| Drug Name: | Quercetin |
| Synonyms: | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 3,3',4',5,7-pentahydroxyflavone; 3,5,7,3',4'-Pentahydroxyflavone; Sophoretin; Xanthaurine; Sigma quercetin |
| Type: | Supplement |
| DrugBank ID: | DB04216 |
| DrugBank Description: | Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. |
| PubChem ID: | 5280343 |
| CasNo: | 117-39-5 |
| Repositioning for NAFLD: | No |
| SMILES: | O=c1c2c(oc(c1O)c1cc(O)c(cc1)O)cc(cc2O)O |
| Structure: |
|
| InChiKey: | REFJWTPEDVJJIY-UHFFFAOYSA-N |
| Molecular Weight: | 302.238 |
| DrugBank Targets: | Tyrosine-protein kinase HCK; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; UDP-glucuronosyltransferase 3A1; ATP synthase subunit alpha, mitochondrial; ATP synthase subunit beta, mitochondrial; ATP synthase subunit gamma, |
| DrugBank MoA: | Quercetin is a specific quinone reductase 2 (QR2) inhibitor, an enzyme (along with the human QR1 homolog) which catalyzes metabolism of toxic quinolines. Inhibition of QR2 in plasmodium may potentially cause lethal oxidative stress. The inhibition of antioxidant activity in plasmodium may contribute to killing the malaria causing parasites. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | AHR; EIF3F; SF3B3; NR1I2 activator |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (IRCT2016060628299N1) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0576 | IRCT2016060628299N1 | Not applicable | Not Recruiting | No Results Available | 13/07/2016 | 22 February 2018 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00261 | 35162967 | Int J Mol Sci | Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis. | Details |
| A00624 | 35024184 | J Adv Res | Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. | Details |
| A00869 | 34944525 | Biomolecules | A System-Level Mechanism of Anmyungambi Decoction for Obesity: A Network Pharmacological Approach. | Details |
| A00881 | 34943104 | Antioxidants (Basel) | The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. | Details |
| A01027 | 34899351 | Front Pharmacol | Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice. | Details |
| A01233 | 34819792 | Saudi Pharm J | Cold-pressed raspberry seeds oil ameliorates high-fat diet triggered non-alcoholic fatty liver disease. | Details |
| A01262 | 34810376 | Saudi J Gastroenterol | Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. | Details |
| A01317 | 34789244 | Lipids Health Dis | Protective effect of quercetin against the metabolic dysfunction of glucose and lipids and its associated learning and memory impairments in NAFLD rats. | Details |
| A01704 | 34649337 | Biomed Pharmacother | Jiangzhi Granule attenuates non-alcoholic steatohepatitis by suppressing TNF/NFκB signaling pathway-a study based on network pharmacology. | Details |
| A02254 | 34445644 | Int J Mol Sci | Resveratrol and Quercetin as Regulators of Inflammatory and Purinergic Receptors to Attenuate Liver Damage Associated to Metabolic Syndrome. | Details |
| A02313 | 34423182 | ACS Omega | Effect of Silymarin and Quercetin in a Miniaturized Scaffold in Wistar Rats against Non-alcoholic Fatty Liver Disease. | Details |
| A02474 | 34360538 | Int J Mol Sci | Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. | Details |
| A02556 | 34329714 | J Ethnopharmacol | Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. | Details |
| A02568 | 34326886 | Evid Based Complement Alternat Med | Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. | Details |
| A02756 | 34257817 | Oxid Med Cell Longev | The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence. | Details |
| A02859 | 34214346 | J Basic Clin Physiol Pharmacol | The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. | Details |
| A03214 | 34087406 | Food Chem Toxicol | Quercetin and non-alcoholic fatty liver disease: A review based on experimental data and bioinformatic analysis. | Details |
| A03447 | 33995543 | Evid Based Complement Alternat Med | Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease. | Details |
| A03460 | 33992930 | Eur J Med Chem | Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. | Details |
| A03796 | 33861449 | Adv Exp Med Biol | Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. | Details |